Immatics Us, Inc.

This study is testing a new personalized treatment for adults with advanced solid tumors that have returned or stopped responding to standard therapies. Doctors take a patient's own immune cells, modify them in a lab to better target their cancer, and then infuse them back. The t…

This is a first-in-human study to test the safety and early effectiveness of a two-part treatment called IMA203 combined with mRNA-4203. It is for people with advanced skin cancer (melanoma) or a rare soft-tissue cancer (synovial sarcoma) that has spread and no longer responds to…

This trial is testing whether a personalized cell therapy called IMA203 works better than standard treatments for advanced melanoma that has spread and hasn't responded to previous therapies. The treatment uses the patient's own immune cells that are specially engineered to attac…